(Q40601626)

21 September 2017

1 reference

title

Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias (English)

1 reference

21 September 2017

main subject

congestive heart failure

1 reference

5

1 reference

21 September 2017

Kupersmith J

1

1 reference

21 September 2017

Holmes-Rovner M

series ordinal

2

1 reference

21 September 2017

Hogan A

series ordinal

3

1 reference

21 September 2017

Rovner D

series ordinal

4

1 reference

21 September 2017

language of work or name

1 reference

1 March 1995

1 reference

Progress in Cardiovascular Diseases

21 September 2017

published in

1 reference

21 September 2017

volume

37

1 reference

21 September 2017

issue

5

1 reference

21 September 2017

page(s)

307-346

1 reference

Cost-effectiveness analysis in heart disease, Part I: General principles

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost-effectiveness analysis in heart disease, Part II: Preventive therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost and health implications of cholesterol lowering

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Care of patients with a low probability of acute myocardial infarction. Cost effectiveness of alternatives to coronary-care-unit admission

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A cost-effectiveness model for coronary thrombolysis/reperfusion therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost and procedure implications of thrombolytic therapy for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The cost:benefit ratio of acute intervention for myocardial infarction: results of a prospective, matched pair analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost-effectiveness analysis of patient management alternatives after uncomplicated myocardial infarction: a model.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Reduction of prehospital, ambulance and community coronary death rates by the community-wide emergency cardiac care system

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Treatment of out-of-hospital cardiac arrests with rapid defibrillation by emergency medical technicians

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Ventricular fibrillation complicating acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. A double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Should lidocaine be administered routinely to all patients after acute myocardial infarction?

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The clinical significance of bundle branch block complicating acute myocardial infarction. 1. Clinical characteristics, hospital mortality, and one-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The risk of pacing after infarction, and current recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The clinical significance of bundle branch block complicating acute myocardial infarction. 2. Indications for temporary and permanent pacemaker insertion

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Stroke and acute Myocardial Infarction in the Thrombolytic era: Clinical correlates and long-term prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Predictors of clinical course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Risk stratification after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Prognostic value of exercise testing, coronary angiography and left ventriculography 6--8 weeks after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Current concepts: evaluation of patients after acute myocardial infarction: indications for cardiac catheterization and surgical intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Noninvasive testing in the evaluation of myocardial ischemia: agreement among tests

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Prevalence of high-risk thallium-201 scintigraphic findings in left main coronary artery stenosis: comparison with patients with multiple- and single-vessel coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Low-level exercise testing after myocardial infarction: usefulness in enhancing clinical risk stratification

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Controlled trial of sotalol for one year after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Multicentre international study: supplementary report

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Prognosis after myocardial infarction: results of 15 year follow up

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Making the coronary care unit cost-effective

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A computer protocol to predict myocardial infarction in emergency department patients with chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A computer-derived protocol to aid in the diagnosis of emergency room patients with acute chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost-effectiveness of interventions to prevent or treat coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The course of patients with suspected myocardial infarction. The identification of low-risk patients for early transfer from intensive care

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Rationing intensive care--physician responses to a resource shortage

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

In-hospital mortality rates from acute myocardial infarction by race in U.S. hospitals: findings from the National Hospital Discharge Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Bayesian comparison of cost-effectiveness of different clinical approaches to diagnose coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The decision concerning coronary angiography in patients with chest pain. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost-effectiveness of screening strategies for left main coronary artery disease in patients with stable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Can exercise electrocardiography and thallium-201 myocardial imaging exclude the diagnosis of coronary artery disease? Bayesian analysis of the clinical limits of exclusion and indications for coronary angiography.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The role of the exercise test in the evaluation of patients for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Prognosis of asymptomatic or mildly symptomatic patients with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Diagnostic value of history and maximal exercise electrocardiography in men and women suspected of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The risk and cost of coronary angiography. I. Cost of coronary angiography in Washington State

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Clinical and angiographic predictors of operative mortality from the collaborative study in coronary artery surgery (CASS)

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Utility Functions for Life Years and Health Status

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The Cost of Coronary Bypass Procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The Variation in Hospital Charges: A Problem in Determining Cost/Benefit for Cardiac Surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Consensus on bypass surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Complications of coronary arteriography: A follow-up report

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Is Percutaneous Coronary Angioplasty Less Expensive Than Bypass Surgery?

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Comparative cost of myocardial revascularization: percutaneous transluminal angioplasty and coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Comparative costs of percutaneous transluminal coronary angioplasty and coronary artery bypass grafting in multivessel coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Relative cost of coronary angioplasty and bypass surgery in a one-vessel disease model

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Medical costs of coronary artery disease in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Analysis of Probability as an Aid in the Clinical Diagnosis of Coronary-Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Relation between high density lipoprotein cholesterol and coronary artery disease in asymptomatic men

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Coronary heart disease risk factor trends in blacks between the first and second National Health and Nutrition Examination Surveys, United States, 1971-1980.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Incidence and progression of coronary artery disease. An angiographic correlation in 1,263 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS)

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Complications of coronary arteriography from the Collaborative Study of Coronary Artery Surgery (CASS)

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

National survey of exercise stress testing facilities

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Computer-assisted diagnosis in the noninvasive evaluation of patients with suspected coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Complications associated with cardiac catheterization and angiography

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Treatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Randomized trials in coronary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Different prognostic value of exercise electrocardiogram in men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Exercise stress testing. Correlations among history of angina, ST-segment response and prevalence of coronary-artery disease in the Coronary Artery Surgery Study (CASS).

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Angiographic follow-up after placement of a self-expanding coronary-artery stent

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Angiographic and clinical outcome of intracoronary stenting: Immediate and long-term results from a large single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Caveats about Elective Coronary Stenting

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost-effectiveness analysis of transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

An analysis of the cost effectiveness of the implantable defibrillator

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost-effectiveness of the implantable cardioverter-defibrillator: Effect of improved battery life and comparison with amiodarone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A computer-based Markov decision analysis of the management of symptomatic bifascicular block: the threshold probability for pacing

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter/defibrillator

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Mortality in patients with implanted automatic defibrillators

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The automatic implantable cardioverter-defibrillator: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The automatic implantable cardioverter defibrillator: Efficacy, complications and survival in patients with malignant ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Clinical characteristics and long-term follow-up in 119 survivors of cardiac arrest: relation to inducibility at electrophysiologic testing

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Long-term mexiletine for ventricular arrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Determinants of survival in patients with ventricular tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Short- and long-term therapy with tocainide for malignant ventricular tachyarrhythmias.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Safety and efficacy of encainide for malignant ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Clinical experience in seventy-seven patients with the automatic implantable cardioverter defibrillator.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Long-term outcome with the automatic implantable cardioverter-defibrillator.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Amiodarone in refractory life-threatening ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Results of late programmed electrical stimulation and long-term electrophysiologic effects of amiodarone therapy in patients with refractory ventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Prognostic value of early electrophysiologic studies for ventricular tachycardia recurrence in patients with coronary artery disease treated with amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Survivors of cardiac arrest: prevention of recurrence by drug therapy as predicted by electrophysiologic testing or electrocardiographic monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Is programmed stimulation of value in predicting the long-term success of antiarrhythmic therapy for ventricular tachycardias?

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Automatic implantable cardioverter defibrillator. Current status

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Automatic implantable cardioverter-defibrillator: patient survival, battery longevity and shock delivery analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Long-term multicenter experience with a second-generation implantable pacemaker-defibrillator in patients with malignant ventricular tachyarrhythmias. The Guardian Multicenter Investigators Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Long-term results of catheter ablation of a posteroseptal accessory atrioventricular connection in 48 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Predictive accuracy of electrophysiologic localization of accessory pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Treatment of Supraventricular Tachycardia Due to Atrioventricular Nodal Reentry by Radiofrequency Catheter Ablation of Slow-Pathway Conduction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Survival rates after pacemaker implantation: a study of patients paced for sick sinus syndrome and atrioventricular block

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The Epidemiology of Pacemaker Implantations in Fyn County, Denmark

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: an international multicenter study. PCD Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Implantable transvenous cardioverter-defibrillators.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Automatic implantable cardioverter-defibrillator: is early implantation cost-effective?

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Atrioventricular block: Natural history after permanent ventricular pacing

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Patients with high-grade atrioventricular block treated and not treated with a pacemaker

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Prognostic value of infranodal conduction time in patients with chronic bundle branch block

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Effect of age on atrioventricular conduction in patients with chronic bifascicular block

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Cost-effectiveness of a smoking cessation program after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

The cost-effectiveness of counseling smokers to quit.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Anticoagulation for Noncardiac Procedures in Patients With Prosthetic Heart Valves

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Screening for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

A cost-effectiveness analysis of exercise as a health promotion activity

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

Confidence intervals for cost-effectiveness ratios.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980017-9

7 January 2021

10.1016/S0033-0620(05)80017-9

Identifiers

DOI

1 reference

21 September 2017

1 reference